Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1138431 | 0.95 | CYP3A4 (0.75) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6922991 | 0.89 | CYP3A4 (0.83) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Linaprazan SCHEMBL1138430 | 0.87 | CYP3A4 (0.93) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4591574 | 0.87 | CYP3A4 (0.89) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Linaprazan SCHEMBL1138353 | 0.85 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL25448140 | 0.83 | CYP3A4 (0.77) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1381726 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6923313 | 0.83 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6923311 | 0.82 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1381723 | 0.82 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004113338-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND I WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |